Please try another search
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Chin-Ting Chiu | - | 2022 | Independent Director |
Wan-Fang Ting | - | 2023 | Director |
Howard S. Lee | - | 2021 | Independent Director |
Tamon Tseng | - | 2016 | Director |
Kung-Yee Liang | - | 2023 | Chairman |
Ming-Chin Chen | 58 | 2022 | Independent Director |
Cheng-En Tsai | - | 2023 | VP of Medical Department & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review